X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1374) 1374
Publication (102) 102
Newsletter (25) 25
Book Review (16) 16
Magazine Article (4) 4
Book Chapter (2) 2
Conference Proceeding (2) 2
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (889) 889
index medicus (848) 848
rosuvastatin (846) 846
rosuvastatin calcium (832) 832
male (769) 769
pharmacology & pharmacy (675) 675
statins (507) 507
female (500) 500
animals (440) 440
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (434) 434
fluorobenzenes - pharmacology (432) 432
middle aged (414) 414
sulfonamides - pharmacology (414) 414
pyrimidines - pharmacology (412) 412
atorvastatin (357) 357
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (341) 341
fluorobenzenes - therapeutic use (296) 296
aged (289) 289
pyrimidines - therapeutic use (282) 282
sulfonamides - therapeutic use (281) 281
adult (272) 272
simvastatin (260) 260
cholesterol (258) 258
antilipemic agents (222) 222
rats (217) 217
pravastatin (198) 198
cardiac & cardiovascular systems (186) 186
pharmacokinetics (181) 181
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (175) 175
treatment outcome (153) 153
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (152) 152
atherosclerosis (151) 151
analysis (149) 149
atorvastatin calcium (149) 149
fluorobenzenes - administration & dosage (148) 148
dose-response relationship, drug (142) 142
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (139) 139
pyrimidines - administration & dosage (139) 139
fluorobenzenes - pharmacokinetics (138) 138
drug interactions (137) 137
mice (137) 137
sulfonamides - administration & dosage (136) 136
hypercholesterolemia (134) 134
lipids (134) 134
cholesterol, ldl - blood (129) 129
dosage and administration (128) 128
research (127) 127
risk (127) 127
pyrimidines - pharmacokinetics (124) 124
sulfonamides - pharmacokinetics (122) 122
rosuvastatin calcium - pharmacology (121) 121
hypercholesterolemia - drug therapy (119) 119
coronary-heart-disease (117) 117
statin (116) 116
prevention (114) 114
fluorobenzenes - adverse effects (112) 112
therapy (111) 111
drug therapy (110) 110
pyrimidines - adverse effects (105) 105
risk factors (105) 105
pharmacology (104) 104
sulfonamides - adverse effects (104) 104
inflammation (103) 103
oxidative stress (102) 102
safety (100) 100
expression (99) 99
cardiovascular disease (97) 97
c-reactive protein (96) 96
cardiovascular (96) 96
drug therapy, combination (96) 96
young adult (93) 93
peripheral vascular disease (91) 91
disease (90) 90
double-blind method (89) 89
efficacy (86) 86
time factors (85) 85
internal medicine (84) 84
rosuvastatin calcium - therapeutic use (84) 84
rats, wistar (83) 83
rosuvastatin calcium - administration & dosage (83) 83
care and treatment (82) 82
disease models, animal (82) 82
statin therapy (82) 82
cells, cultured (80) 80
low density lipoproteins (80) 80
nutritional and metabolic diseases (80) 80
pyrroles - pharmacology (80) 80
cholesterol - blood (79) 79
rats, sprague-dawley (79) 79
health aspects (78) 78
heptanoic acids - pharmacology (78) 78
pharmacology/toxicology (78) 78
medicine & public health (77) 77
area under curve (75) 75
cross-over studies (75) 75
heptanoic acids - therapeutic use (75) 75
nitric-oxide synthase (75) 75
cardiology (74) 74
cardiovascular-disease (74) 74
pyrroles - therapeutic use (74) 74
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1377) 1377
Russian (10) 10
Chinese (9) 9
French (3) 3
Japanese (3) 3
Spanish (2) 2
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PLoS ONE, ISSN 1932-6203, 03/2016, Volume 11, Issue 3, p. e0151592
Rosuvastatin is a member of the statin family. Like the other statins it is prescribed to lower cholesterol levels and thereby reduce the risk of... 
METAANALYSIS | MULTIDISCIPLINARY SCIENCES | CA2+ CHANNELS | RIM | INVOLVEMENT | PANCREATIC BETA-CELLS | RAB3 EFFECTOR | PRAVASTATIN | SIMVASTATIN | STATINS | ATORVASTATIN | Membrane Potentials - drug effects | Mevalonic Acid - pharmacology | Cell Line | Diazoxide - pharmacology | Vasodilator Agents - pharmacology | Calcium Channels - metabolism | Calcium - metabolism | Rosuvastatin Calcium - pharmacology | Rats | Glucose - pharmacology | Dose-Response Relationship, Drug | KATP Channels - metabolism | Insulin - metabolism | Insulin-Secreting Cells - metabolism | Patch-Clamp Techniques | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Insulin-Secreting Cells - drug effects | Insulin Secretion | Ion Channel Gating - drug effects | Care and treatment | Rosuvastatin | Research | Cardiovascular diseases | Health aspects | Insulin | Systematic review | Biosynthesis | Glucose | Exocytosis | Experiments | Channels | Depolarization | Coupling (molecular) | Reduction | Mevalonic acid | Rodents | Inhibition | Statins | Stimulus-secretion coupling | Calcium channels | Secretion | Calcium channels (voltage-gated) | Health risks | Squalene | Risk reduction | Metabolism | Cholesterol | Side effects | Molecular modelling | Insulin resistance | Hydroxymethylglutaryl-CoA reductase | Diabetes | Potassium | Endocrinology | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 10/2015, Volume 764, pp. 283 - 291
The present study was carried out to evaluate the protective effect of different statins on isoproterenol (ISO) induced myocardial necrosis. Atorvastatin,... 
Fluvastatin | Simvastatin | Atorvastatin | Rosuvastatin | Myocardial necrosis | Isoproterenol | Pravastatin | CHRONIC HEART-FAILURE | COENZYME-A REDUCTASE | CHOLESTEROL | INFARCTION | PLASMA | PHARMACOLOGY & PHARMACY | RAT-HEART | LIPOPROTEINS | STATIN TREATMENT | Necrosis - drug therapy | Myocardial Infarction - chemically induced | Simvastatin - therapeutic use | Fatty Acids, Monounsaturated - pharmacology | Rosuvastatin Calcium - therapeutic use | Rats, Wistar | Atorvastatin Calcium - pharmacology | Glutathione - metabolism | Cholesterol - blood | Male | Simvastatin - pharmacology | Necrosis - pathology | Cardiotonic Agents - therapeutic use | Fatty Acids, Monounsaturated - therapeutic use | Myocardial Infarction - pathology | Myocardium - metabolism | Indoles - pharmacology | Pravastatin - therapeutic use | Atorvastatin Calcium - therapeutic use | Superoxide Dismutase - metabolism | Pravastatin - pharmacology | Blood Glucose - analysis | Rosuvastatin Calcium - pharmacology | Adenosine Triphosphatases - metabolism | Myocardium - pathology | Necrosis - metabolism | Cardiotonic Agents - pharmacology | Myocardial Infarction - metabolism | Necrosis - chemically induced | Catalase - metabolism | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Myocardial Infarction - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Isoproterenol - pharmacology | Triglycerides - blood | Indoles - therapeutic use | Isoproterenol - therapeutic use | Antioxidants | Pharmacy | Drugstores | Glucose | Comparative analysis | Statins | Dextrose | Necrosis
Journal Article
Thrombosis Research, ISSN 0049-3848, 2016, Volume 150, pp. 90 - 95
Abstract Background Statins represent a pivotal treatment in coronary artery disease, offering a reduction in cardiovascular risk even beyond their... 
Hematology, Oncology and Palliative Medicine | Platelet aggregation | Vitamin D | Coronary artery disease | Statins | RANDOMIZED-TRIALS | CARDIOVASCULAR EVENTS | D DEFICIENCY | RISK | ISCHEMIC-HEART-DISEASE | ATORVASTATIN | DENSITY-LIPOPROTEIN CHOLESTEROL | ANGIOPLASTY | THERAPY | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ELEVATION MYOCARDIAL-INFARCTION | Blood Platelets - pathology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - therapeutic use | Rosuvastatin Calcium - therapeutic use | Atorvastatin Calcium - pharmacology | Atorvastatin Calcium - administration & dosage | Humans | Middle Aged | Male | Simvastatin - pharmacology | Coronary Artery Disease - blood | Rosuvastatin Calcium - administration & dosage | Dose-Response Relationship, Drug | Platelet Aggregation Inhibitors - administration & dosage | Coronary Artery Disease - pathology | Platelet Aggregation Inhibitors - pharmacology | Female | Platelet Aggregation - drug effects | Blood Platelets - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Atorvastatin Calcium - therapeutic use | Simvastatin - administration & dosage | Rosuvastatin Calcium - pharmacology | Coronary Artery Disease - drug therapy | Vitamin D - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Aged | Care and treatment | Cardiac patients | Calcifediol | Dosage and administration | Alfacalcidol | Coronary heart disease | Cardiovascular agents | Hypercholesterolemia | Thrombin | Cardiology
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2016, Volume 100, Issue 3, pp. 259 - 267
Journal Article
Journal Article
Pharmacological Research, ISSN 1043-6618, 05/2016, Volume 107, pp. 1 - 18
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 11/2015, Volume 43, Issue 11, pp. 1788 - 1794
Unbound plasma concentrations may not reflect those in target tissues, and there is a need for methods to predict tissue partitioning. Here, we investigate the... 
Animals | Humans | Rosuvastatin Calcium - pharmacology | HEK293 Cells | Macaca fascicularis | Female | Male | Hepatocytes - metabolism | Rosuvastatin Calcium - metabolism | Forecasting | Hepatocytes - drug effects | Protein Binding - physiology
Journal Article